表紙
市場調查報告書

到慢性自發性蕁麻疹(CSU):至2030年的流行病學預測

Chronic spontaneous urticaria (CSU) - Epidemiology Forecast - 2030

出版商 DelveInsight Business Research LLP 商品編碼 952556
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
到慢性自發性蕁麻疹(CSU):至2030年的流行病學預測 Chronic spontaneous urticaria (CSU) - Epidemiology Forecast - 2030
出版日期: 2020年08月01日內容資訊: 英文 100 Pages
簡介

慢性蕁麻疹,特徵是癢的疾病,有無血管性水腫的情況,是繼續6週以上的衰弱性疾病。慢性蕁麻疹由於皮膚搔抓,運動,情緒激動(膽素型蕁麻疹),感冒,熱,壓力,日光(太陽蕁麻疹),水等各種化學物質的接觸(接觸蕁麻疹),震動所引起。因此,引起的蕁麻疹稱為慢性引起的蕁麻疹(CIndU)。但是,慢性蕁麻疹更常見是內源性的,並且不受任何外部原因的影響。這種蕁麻疹被稱為慢性自發性蕁麻疹(CSU)。

本報告提供主要7個國家關於(美國,德國,法國,義大利,西班牙,英國,日本)至2030年的CSU的流行病學展望調查,疾病與概要,流行病學患者數,各國流行病學,現在所進行的治療,主要的專家見解等資訊。

目錄

第1章 主要調查結果

第2章 摘要整理

第3章 組織

第4章 流行病學與市場調查技術

第5章 市場概要

  • 2017年的市場佔有率
  • 2030年的市場佔有率

第6章 疾病概要

  • 簡介
  • 分類
  • 原因
  • 徵兆與症狀
  • 臨床表現
  • 病因
  • 診斷
  • 治療

第7章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的病例
  • 美國
    • 假設和根據
    • 盛行率的總合
    • 性別特異性病例
    • 各年齡病例
  • 歐洲5個國家
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第8章 主要專家的見解

第9章 附錄

第10章 調查手法

章11章 DelveInsight的服務內容

第12章 免責聲明

第13章 關於DelveInsight

目錄
Product Code: DIEI0979

DelveInsight's 'Chronic spontaneous urticaria (CSU) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Chronic spontaneous urticaria (CSU), historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Chronic spontaneous urticaria (CSU) Disease Understanding

Chronic urticaria is a debilitating disease that is characterized by itching and hives with or without angioedema, lasting for more than 6 weeks. Chronic urticaria might be triggered due to stimuli such as stroking or scratching the skin, exercise, emotional upset (cholinergic urticaria), cold, heat, pressure, sunlight (solar urticaria), contact with water or various chemicals (contact urticaria), or vibration. Urticaria induced, thus, is known as chronic induced urticaria (CIndU). However, more commonly chronic urticaria is endogenous and independent of any external causes. This urticaria is known as chronic spontaneous urticaria (CSU).

However, there are still few unmet needs in the understanding of disease etiology in cases where autoimmunity is ruled out. Quality of life is severely impacted in CSU patients due to unpredictability of attacks, fatigue caused by treatment side effects, and cosmetic disfigurement. Patients with CSU often exhibit psychiatric comorbidities.

Chronic spontaneous urticaria (CSU) Epidemiology

The Chronic spontaneous urticaria (CSU) epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of Chronic spontaneous urticaria (CSU) patients are increasing in 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Chronic spontaneous urticaria (CSU) symptoms epidemiology segmented as the Total Prevalent cases of Chronic spontaneous urticaria (CSU), Gender-specific cases of Chronic spontaneous urticaria (CSU), Age-specific cases of Chronic spontaneous urticaria (CSU). The report includes the prevalent scenario of Chronic spontaneous urticaria (CSU) symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- Chronic spontaneous urticaria (CSU) Epidemiology

The epidemiology segment also provides the Chronic spontaneous urticaria (CSU) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total prevalent cases of Chronic spontaneous urticaria (CSU) associated in 7MM countries was 1,169,632 in 2017.

  • As per the estimates, the United States has the largest prevalent population of Chronic spontaneous urticaria (CSU).
  • Among the EU5 countries, Germany had the highest prevalent cases of Chronic spontaneous urticaria (CSU), followed by France. On the other hand, Spain had the lowest prevalent cases with 75,069 cases in 2017.

Scope of the Report:

  • The Chronic spontaneous urticaria (CSU) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns.
  • The Chronic spontaneous urticaria (CSU) Epidemiology Report and Model provide an overview of the risk factors and global trends of Chronic spontaneous urticaria (CSU) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight about the historical and forecasted patient pool of Chronic spontaneous urticaria (CSU) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Chronic spontaneous urticaria (CSU).
  • The report provides the segmentation of the Chronic spontaneous urticaria (CSU) epidemiology by Prevalent Cases of Chronic spontaneous urticaria (CSU) in 7MM.
  • The report provides the segmentation of the Chronic spontaneous urticaria (CSU) epidemiology by Gender-Specific Prevalent Cases of Chronic spontaneous urticaria (CSU) in 7MM.
  • The report provides the segmentation of the Chronic spontaneous urticaria (CSU) epidemiology by Age-Specific Prevalent Cases of Chronic spontaneous urticaria (CSU) in 7MM.

Report Highlights:

  • 11-Year Forecast of Chronic spontaneous urticaria (CSU) epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Chronic spontaneous urticaria (CSU)
  • Prevalent Cases according to segmentation: Gender-specific cases of Chronic spontaneous urticaria (CSU)
  • Prevalent Cases according to segmentation: Age-specific cases of Chronic spontaneous urticaria (CSU)

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic spontaneous urticaria (CSU)?
  • What are the key findings pertaining to the Chronic spontaneous urticaria (CSU) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Chronic spontaneous urticaria (CSU) across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Chronic spontaneous urticaria (CSU)?
  • What are the currently available treatments of Chronic spontaneous urticaria (CSU)?

Reasons to buy:

The Chronic spontaneous urticaria (CSU) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Chronic spontaneous urticaria (CSU) market
  • Quantify patient populations in the global Chronic spontaneous urticaria (CSU) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Chronic spontaneous urticaria (CSU) therapeutics in each of the markets covered
  • Understand the magnitude of Chronic spontaneous urticaria (CSU) population by its Prevalence cases
  • Understand the magnitude of Chronic spontaneous urticaria (CSU) population by its Gender-specific cases
  • Understand the magnitude of Chronic spontaneous urticaria (CSU) population by its Age-specific cases
  • The Chronic spontaneous urticaria (CSU) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
  • The Chronic spontaneous urticaria (CSU) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Vietri et al. (2015) tried to estimate the effect of urticaria on the US population and prevalence using a retrospective, cross-sectional analysis of data taken from the US National Health and Wellness Survey (NHWS)-a large, cross-sectional survey designed to reflect health in the general population. The estimates used were close to Hellgran 1972 results, i.e., the point prevalence of 0.1%; however, the prevalence is thought to be increased over the last few decades.

Only a few studies have examined the prevalence of CSU in European countries. Lapi et al. (2015), used the Health Search IMS Health Longitudinal Patient Database (HSD), a longitudinal observational database established in 1998 by the Italian College of GPs, containing the electronic patient records from approximately 1000 GPs throughout Italy. Computer-based patient records collected by a selected group of 700 GPs, who met standard quality criteria regarding the levels of data entry, were included in the estimation of CSU prevalence in Italy.

Table of Contents

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 Chronic Spontaneous Urticaria: Market Overview at a Glance

  • 5.1 Total Market Share (%) Distribution of Chronic Spontaneous Urticaria in 2017
  • 5.2 Total Market Share (%) Distribution of Chronic Spontaneous Urticaria in 2030

6 Chronic Spontaneous Urticaria: Market Overview at a Glance

  • 6.1 Introduction
  • 6.2 Classification
  • 6.3 Causes
  • 6.4 Signs and Symptoms
  • 6.5 Clinical Presentation
  • 6.6 Pathogenesis
  • 6.7 Diagnosis

Diagnostic Guidelines

Differential Diagnosis

  • 6.8 Treatment

Other treatments

The EAACI/GA²LEN/EDF/WAO guideline

7 Epidemiology and Patient Population

  • 7.1 Key Findings
  • 7.2 Total cases of Chronic Spontaneous Urticaria in 7MM
  • 7.3 United States
    • 7.3.1 Assumptions and Rationale
    • 7.3.2 Total Prevalent cases of Chronic Spontaneous Urticaria in the United States
    • 7.3.3 Gender-Specific cases of Chronic Spontaneous Urticaria in the United States
    • 7.3.4 Age-specific cases of Chronic Spontaneous Urticaria in the United States
  • 7.4 EU5 Countries
    • 7.4.1 Assumptions and Rationale
  • 7.5 Germany
    • 7.5.1 Total Prevalent cases of Chronic Spontaneous Urticaria in Germany
    • 7.5.2 Gender-Specific cases of Chronic Spontaneous Urticaria in Germany
    • 7.5.3 Age-specific cases of Chronic Spontaneous Urticaria in Germany
  • 7.6 France
    • 7.6.1 Total Prevalent cases of Chronic Spontaneous Urticaria in France
    • 7.6.2 Gender-Specific cases of Chronic Spontaneous Urticaria in France
    • 7.6.3 Age-specific cases of Chronic Spontaneous Urticaria France
  • 7.7 Italy
    • 7.7.1 Total Prevalent cases of Chronic Spontaneous Urticaria in Italy
    • 7.7.2 Gender-Specific cases of Chronic Spontaneous Urticaria in Italy
    • 7.7.3 Age-specific cases of Chronic Spontaneous Urticaria in Italy
  • 7.8 Spain
    • 7.8.1 Total Prevalent cases of Chronic Spontaneous Urticaria in Spain
    • 7.8.2 Gender-Specific cases of Chronic Spontaneous Urticaria in Spain
    • 7.8.3 Age-specific cases of Chronic Spontaneous Urticaria Spain
  • 7.9 UK
    • 7.9.1 Total Prevalent cases of Chronic Spontaneous Urticaria in the United Kingdom
    • 7.9.2 Gender-Specific cases of Chronic Spontaneous Urticaria in the United Kingdom
    • 7.9.3 Age-specific cases of Chronic Spontaneous Urticariain the United Kingdom
  • 7.10. Japan
    • 7.10.1 Assumptions and Rationale
    • 7.10.2 Total Prevalent cases of Chronic Spontaneous Urticaria in Japan
    • 7.10.3 Gender-Specific cases of Chronic Spontaneous Urticaria in Japan
    • 7.10.4 Age-specific cases of Chronic Spontaneous Urticaria in Japan

8 KOL Views

9 Appendix

10 Report Methodology

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight

List of Tables

  • Table 1: Classification of Urticaria
  • Table 2: Etiology
  • Table 3: Urticaria-Associated History And Physical Examination Findings with Possible Etiologies
  • Table 4: Urticaria-Associated History And Physical Examination Findings with Possible Etiologies
  • Table 5: Conditions That May Be Confused with Urticaria
  • Table 6: Treatment Algorithm For Urticaria Recommended by EAACI, GA2LEN, EDF, WOA
  • Table 7: Approaches To Consider When Antihistamines Fail
  • Table 8:Treatment Algorithm Recommended by the Dermato-Allergy Working Group of the Turkish Society of Dermatology And the Turkish Dermato-Immunology And Allergy Association
  • Table 9: Should Patients with Chronic Spontaneous Urticaria Be Advised To Discontinue A Medication That Is Suspected of Worsening the Disease?
  • Table 10: Total Cases of Chronic Spontaneous Urticaria in 7MM (2017-2030)
  • Table 11: Total Prevalent Cases of Chronic Spontaneous Urticaria in the United States (2017-2030)
  • Table 12: Gender-Specific Cases of Chronic Spontaneous Urticaria in the US (2017-2030)
  • Table 13: Age-Specific Cases of Chronic Spontaneous Urticaria in the US (2017-2030)
  • Table 14: Total Prevalent Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Table 15: Gender-Specific Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Table 16: Age-Specific Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Table 17: Total Prevalent Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Table 18: Gender-Specific Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Table 19: Age-Specific Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Table 20: Total Prevalent Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Table 21: Gender-Specific Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Table 22: Age-Specific Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Table 23: Total Prevalent Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Table 24: Gender-Specific Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Table 25: Age-Specific Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Table 26: Total Prevalent Cases of Chronic Spontaneous Urticaria in the United Kingdom (2017-2030)
  • Table 27: Gender-Specific Cases of Chronic Spontaneous Urticaria in the UK (2017-2030)
  • Table 28: Age-Specific Cases of Chronic Spontaneous Urticaria in the UK (2017-2030)
  • Table 29: Total Prevalent Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Table 30: Gender-Specific Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Table 31: Age-Specific Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)

List of Figures

  • Figure 1: Epidemiology And Market Methodology
  • Figure 2: Pathophysiology of Chronic Spontaneous Urticaria
  • Figure 3: Model of the Mechanisms Underlying Chronic Urticaria
  • Figure 4: Step-Care Approach To the Treatment For Chronic Urticaria
  • Figure 5: Chronic Urticaria Treatment Guideline
  • Figure 6: Total Cases of Chronic Spontaneous Urticaria in 7MM (2017-2030)
  • Figure 7: Total Prevalent Cases of Chronic Spontaneous Urticaria in the United States (2017-2030)
  • Figure 8: Gender-Specific Cases of Chronic Spontaneous Urticaria in the US (2017-2030)
  • Figure 9: Age-Specific Cases of Chronic Spontaneous Urticaria in the US (2017-2030)
  • Figure 10: Total Prevalent Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Figure 11: Gender-Specific Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Figure 12: Age-Specific Cases of Chronic Spontaneous Urticaria in Germany (2017-2030)
  • Figure 13: Total Prevalent Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Figure 14: Gender-Specific Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Figure 15: Age-Specific Cases of Chronic Spontaneous Urticaria in France (2017-2030)
  • Figure 16: Total Prevalent Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Figure 17: Gender-Specific Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Figure 18: Age-Specific Cases of Chronic Spontaneous Urticaria in Italy (2017-2030)
  • Figure 19: Total Prevalent Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Figure 20: Gender-Specific Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Figure 21: Age-Specific Cases of Chronic Spontaneous Urticaria in Spain (2017-2030)
  • Figure 22: Total Prevalent Cases of Chronic Spontaneous Urticaria in the United Kingdom (2017-2030)
  • Figure 23: Gender-Specific Cases of Chronic Spontaneous Urticaria in the UK (2017-2030)
  • Figure 24: Age-Specific Cases of Chronic Spontaneous Urticaria in the UK (2017-2030)
  • Figure 25: Total Prevalent Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Figure 26: Gender-Specific Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)
  • Figure 27: Age-Specific Cases of Chronic Spontaneous Urticaria in Japan (2017-2030)